Intervention
cytopenia, CRF
DISEASE, CRF, CYTOPENIA
Randomized patients received 0.5 mL of either homologous RBD-TT conjugated or heterologous inactivated COVID-19 booster dose injected intramuscularly into the deltoid area. All patients were visited before (at baseline) and four weeks ( ± 7 days) after the booster, and their blood samples were taken for immunogenicity assessment. All participants were also followed-up through weekly telenursing calls for safety monitoring, any occurrences of COVID-19, relapse of underlying disease, or cytopenia to Mar 21, 2023. Data from the case report forms (CRF) were entered and managed on electronic data capture forms developed on the web-based software of the institution.We employed the ChemoBind SARS-CoV-2 Neutralizing Antibody Test Kit (ChemoBind, Tehran, Iran) to assess the overall antibodies targeting the receptor-binding domain (RBD) spike protein of SARS-CoV-2 through a semi-quantitative immunoassay. As per the manufacturer’s guidelines, an immune status ratio (ISR) for immunoglobulin G (IgG) below 0.8 indicates a negative result, while an ISR above 1.1 indicates a positive result. Ratios falling between these thresholds are inconclusive and require repetition.